Targeting prion proteins in neurodegenerative disease

Bibliography

• DeArmond SJ, Prusiner SB. Etiology and pathogenesis of prion diseases. Am J Pathol 1995;146:785-811
   PubMed Web of Science ®Google Scholar
• Prusiner SB. Prions. Proc Natl Acad Sci USA 1998;95:13363-83
   PubMed Web of Science ®Google Scholar
• Weissmann C. The state of the prion. Nat Rev Microbiol 2004;2:861-71
   PubMed Web of Science ®Google Scholar
• Aguzzi A, Polymenidou M. Mammalian prion biology: one century of evolving concepts. Cell 2004;116:313-27
   PubMed Web of Science ®Google Scholar
• Collinge J. Molecular neurology of prion disease. J Neurol Neurosurg Psychiatry 2005;76:906-19
   PubMed Web of Science ®Google Scholar
• Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982;216:136-44
   PubMed Web of Science ®Google Scholar
• Cohen FE, Pan KM, Huang Z, et al. Structural clues to prion replication. Science 1994;264:530-1
   PubMed Web of Science ®Google Scholar
• Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Ann Rev Neurosci 2001;24:519-50
   PubMed Web of Science ®Google Scholar
• Aguzzi A, Haass C. Games played by rogue proteins in prion disorders and Alzheimer's disease. Science 2003;302:814-8
   PubMed Web of Science ®Google Scholar
• Dobson CM. Protein aggregation and its consequences for human disease. Protein Pept Lett 2006;13:219-27
   PubMed Web of Science ®Google Scholar
• Weissmann C, Fischer M, Raeber A, et al. The use of transgenic mice in the investigation of transmissible spongiform encephalopathies. Int J Exp Pathol 1996;77:283-93
   PubMed Web of Science ®Google Scholar
• Gajdusek DC. Unconventional viruses and the origin and disappearance of kuru. Science 1977;197:943-60
   PubMed Web of Science ®Google Scholar
• Collinge J, Sidle KC, Meads J, et al. Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature 1996;383:685-90
   PubMed Web of Science ®Google Scholar
• Anderson RM, Donnelly CA, Ferguson NM, et al. Transmission dynamics and epidemiology of BSE in British cattle. Nature 1996;382:779-88
   PubMed Web of Science ®Google Scholar
• Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature 1997;389:498-501
   PubMed Web of Science ®Google Scholar
• Hill AF, Desbruslais M, Joiner S, et al. The same prion strain causes vCJD and BSE. Nature 1997;389:448-50, 526
   PubMed Web of Science ®Google Scholar
• Wadsworth JD, Joiner S, Hill AF, et al. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 2001;358:171-80
   PubMed Web of Science ®Google Scholar
• Sigurdson CJ, Miller MW. Other animal prion diseases. Br Med Bull 2003;66:199-212
   PubMed Web of Science ®Google Scholar
• Angers RC, Browning SR, Seward TS, et al. Prions in skeletal muscles of deer with chronic wasting disease. Science 2006;311:1117
   PubMed Web of Science ®Google Scholar
• Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004;364:527-9
   PubMed Web of Science ®Google Scholar
• Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004;363:417-21
   PubMed Web of Science ®Google Scholar
• Wroe SJ, Pal S, Siddique D, et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 2006;368:2061-7
   PubMed Web of Science ®Google Scholar
• Hewitt PE, Llewelyn CA, MacKenzie J, et al. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang 2006;91:221-30
   PubMed Web of Science ®Google Scholar
• Westergard L, Christensen HM, Harris DA. The cellular prion protein (PrP(C)): its physiological function and role in disease. Biochim Biophys Acta 2007;1772:629-44
   PubMed Web of Science ®Google Scholar
• Caughey B, Baron GS. Prions and their partners in crime. Nature 2006;443:803-10
   PubMed Web of Science ®Google Scholar
• Hundt C, Peyrin JM, Haik S, et al. Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor. EMBO J 2001;20:5876-86
   PubMed Web of Science ®Google Scholar
• Leucht C, Simoneau S, Rey C, et al. The 37 kDa/67 kDa laminin receptor is required for PrP(Sc) propagation in scrapie-infected neuronal cells. EMBO Rep 2003;4:290-5
   PubMed Web of Science ®Google Scholar
• Vella LJ, Sharples RA, Lawson VA, et al. Packaging of prions into exosomes is associated with a novel pathway of PrP processing. J Pathol 2007;211:582-90
   PubMed Web of Science ®Google Scholar
• Tatzelt J, Schatzl HM. Molecular basis of cerebral neurodegeneration in prion diseases. FEBS J 2007;274:606-11
   PubMed Web of Science ®Google Scholar
• Bueler H, Fischer M, Lang Y, et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 1992;356:577-82
   PubMed Web of Science ®Google Scholar
• Tobler I, Gaus SE, Deboer T, et al. Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature 1996;380:639-42
   PubMed Web of Science ®Google Scholar
• Collinge J, Whittington MA, Sidle KC, et al. Prion protein is necessary for normal synaptic function. Nature 1994;370:295-7
   PubMed Web of Science ®Google Scholar
• Colling SB, Collinge J, Jefferys JG. Hippocampal slices from prion protein null mice: disrupted Ca(2+)-activated K+ currents. Neurosci Lett 1996;209:49-52
   PubMed Web of Science ®Google Scholar
• McLennan NF, Brennan PM, McNeill A, et al. Prion protein accumulation and neuroprotection in hypoxic brain damage. Am J Pathol 2004;165:227-35
   PubMed Web of Science ®Google Scholar
• Weise J, Crome O, Sandau R, et al. Upregulation of cellular prion protein (PrPc) after focal cerebral ischemia and influence of lesion severity. Neurosci Lett 2004;372:146-50
   PubMed Web of Science ®Google Scholar
• Spudich A, Frigg R, Kilic E, et al. Aggravation of ischemic brain injury by prion protein deficiency: role of ERK-1/-2 and STAT-1. Neurobiol Dis 2005;20:442-9
   PubMed Web of Science ®Google Scholar
• Kuwahara C, Takeuchi AM, Nishimura T, et al. Prions prevent neuronal cell-line death. Nature 1999;400:225-6
   PubMed Web of Science ®Google Scholar
• Chiarini LB, Freitas AR, Zanata SM, et al. Cellular prion protein transduces neuroprotective signals. EMBO J 2002;21:3317-26
   PubMed Web of Science ®Google Scholar
• Lee DC, Sakudo A, Kim CK, et al. Fusion of Doppel to octapeptide repeat and N-terminal half of hydrophobic region of prion protein confers resistance to serum deprivation. Microbiol Immunol 2006;50:203-9
   PubMed Web of Science ®Google Scholar
• Bueler H, Aguzzi A, Sailer A, et al. Mice devoid of PrP are resistant to scrapie. Cell 1993;73:1339-47
   PubMed Web of Science ®Google Scholar
• Brandner S, Isenmann S, Raeber A, et al. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 1996;379:339-43
   PubMed Web of Science ®Google Scholar
• Mallucci GR, Ratte S, Asante EA, et al. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J 2002;21:202-10
   PubMed Web of Science ®Google Scholar
• Mallucci G, Dickinson A, Linehan J, et al. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 2003;302:871-4
   PubMed Web of Science ®Google Scholar
• Mallucci GR, White MD, Farmer M, et al. Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron 2007;53:325-35
   PubMed Web of Science ®Google Scholar
• Chesebro B, Trifilo M, Race R, et al. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 2005;308:1435-9
   PubMed Web of Science ®Google Scholar
• Novitskaya V, Bocharova OV, Bronstein I, et al. Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J Biol Chem 2006;281:13828-36
   PubMed Web of Science ®Google Scholar
• Simoneau S, Rezaei H, Sales N, et al. In vitro and in vivo neurotoxicity of prion protein oligomers. PLoS Pathog 2007;3:e125
   PubMed Web of Science ®Google Scholar
• Silveira JR, Raymond GJ, Hughson AG, et al. The most infectious prion protein particles. Nature 2005;437:257-61
   PubMed Web of Science ®Google Scholar
• Hay B, Barry RA, Lieberburg I, et al. Biogenesis and transmembrane orientation of the cellular isoform of the scrapie prion protein. Mol Cell Biol 1987;7:914-20. Errratum appears in: Mol Cell Biol 1987;7(5):2035
   Google Scholar
• Hegde RS, Mastrianni JA, Scott MR, et al. A transmembrane form of the prion protein in neurodegenerative disease. Science 1998;279:827-34
   PubMed Web of Science ®Google Scholar
• Ma J, Wollmann R, Lindquist S. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science 2002;298:1781-5
   PubMed Web of Science ®Google Scholar
• Wang X, Wang F, Arterburn L, et al. The interaction between cytoplasmic prion protein and the hydrophobic lipid core of membrane correlates with neurotoxicity. J Biol Chem 2006;281:13559-65
   PubMed Web of Science ®Google Scholar
• Rambold AS, Miesbauer M, Rapaport D, et al. Association of Bcl-2 with misfolded prion protein is linked to the toxic potential of cytosolic PrP. Mol Biol Cell 2006;17:3356-68
   PubMed Web of Science ®Google Scholar
• Ma J, Lindquist S. Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol. Science 2002;298:1785-88
   PubMed Web of Science ®Google Scholar
• Heller U, Winklhofer KF, Heske J, et al. Post-translational import of the prion protein into the endoplasmic reticulum interferes with cell viability: a critical role for the putative transmembrane domain. J Biol Chem 2003;278:36139-47
   PubMed Web of Science ®Google Scholar
• Rane NS, Yonkovich JL, Hegde RS. Protection from cytosolic prion protein toxicity by modulation of protein translocation. EMBO J 2004;23:4550-9
   PubMed Web of Science ®Google Scholar
• Kristiansen M, Messenger MJ, Klohn PC, et al. Disease-related prion protein forms aggresomes in neuronal cells leading to caspase activation and apoptosis. J Biol Chem 2005;280:38851-61
   PubMed Web of Science ®Google Scholar
• Kristiansen M, Deriziotis P, Dimcheff DE, et al. Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell 2007;26:175-88
   PubMed Web of Science ®Google Scholar
• Zanusso G, Petersen RB, Jin T, et al. Proteasomal degradation and N-terminal protease resistance of the codon 145 mutant prion protein. J Biol Chem 1999;274:23396-404
   PubMed Web of Science ®Google Scholar
• Heske J, Heller U, Winklhofer KF, et al. The C-terminal globular domain of the prion protein is necessary and sufficient for import into the endoplasmic reticulum. J Biol Chem 2004;279:5435-43
   PubMed Web of Science ®Google Scholar
• Fioriti L, Dossena S, Stewart LR, et al. Cytosolic prion protein (PrP) is not toxic in N2a cells and primary neurons expressing pathogenic PrP mutations. J Biol Chem 2005;280:11320-8
   PubMed Web of Science ®Google Scholar
• Krammer C, Suhre MH, Kremmer E, et al. Prion protein/protein interactions: Fusion with yeast Sup35p-NM modulates cytosolic PrP aggregation in mammalian cells. FASEB J 2008;22:762-73
   PubMed Web of Science ®Google Scholar
• Shmerling D, Hegyi I, Fischer M, et al. Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell 1998;93:203-14
   PubMed Web of Science ®Google Scholar
• Flechsig E, Shmerling D, Hegyi I, et al. Prion protein devoid of the octapeptide repeat region restores susceptibility to scrapie in PrP knockout mice. Neuron 2000;27:399-408
   PubMed Web of Science ®Google Scholar
• Flechsig E, Hegyi I, Leimeroth R, et al. Expression of truncated PrP targeted to Purkinje cells of PrP knockout mice causes Purkinje cell death and ataxia. EMBO J 2003;22:3095-101
   PubMed Web of Science ®Google Scholar
• Baumann F, Tolnay M, Brabeck C, et al. Lethal recessive myelin toxicity of prion protein lacking its central domain. EMBO J 2007;26:538-47
   PubMed Web of Science ®Google Scholar
• Li A, Christensen HM, Stewart LR, et al. Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105-125. EMBO J 2007;26:548-58
   PubMed Web of Science ®Google Scholar
• Moore RC, Mastrangelo P, Bouzamondo E, et al. Doppel-induced cerebellar degeneration in transgenic mice. Proc Natl Acad Sci USA 2001;98:15288-93
   PubMed Web of Science ®Google Scholar
• Nishida N, Tremblay P, Sugimoto T, et al. A mouse prion protein transgene rescues mice deficient for the prion protein gene from purkinje cell degeneration and demyelination. Lab Invest 1999;79:689-97
   PubMed Web of Science ®Google Scholar
• Moore RC, Lee IY, Silverman GL, et al. Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein doppel. J Mol Biol 1999;292:797-817
   PubMed Web of Science ®Google Scholar
• Silverman GL, Qin K, Moore RC, et al. Doppel is an N-glycosylated, glycosylphosphatidylinositol-anchored protein. Expression in testis and ectopic production in the brains of Prnp(0/0) mice predisposed to Purkinje cell loss. J Biol Chem 2000;275:26834-41
   PubMed Web of Science ®Google Scholar
• Behrens A, Genoud N, Naumann H, et al. Absence of the prion protein homologue Doppel causes male sterility. EMBO J 2002;21:3652-8
   PubMed Web of Science ®Google Scholar
• Paisley D, Banks S, Selfridge J, et al. Male infertility and DNA damage in Doppel knockout and prion protein/Doppel double-knockout mice. Am J Pathol 2004;164:2279-88
   PubMed Web of Science ®Google Scholar
• Cui T, Holme A, Sassoon J, et al. Analysis of doppel protein toxicity. Mol Cell Neurosci 2003;23:144-55
   PubMed Web of Science ®Google Scholar
• Premzl M, Sangiorgio L, Strumbo B, et al. Shadoo, a new protein highly conserved from fish to mammals and with similarity to prion protein. Gene 2003;314:89-102
   PubMed Web of Science ®Google Scholar
• Premzl M, Gamulin V. Comparative genomic analysis of prion genes. BMC Genomics 2007;8:1
   PubMed Web of Science ®Google Scholar
• Watts JC, Drisaldi B, Ng V, et al. The CNS glycoprotein Shadoo has PrP(C)-like protective properties and displays reduced levels in prion infections. EMBO J 2007;26:4038-50
   PubMed Web of Science ®Google Scholar
• Macario AJ, Conway dM. Sick chaperones, cellular stress, and disease. N Engl J Med 2005;353:1489-501
   PubMed Web of Science ®Google Scholar
• Vernace VA, Schmidt-Glenewinkel T, Figueiredo-Pereira ME. Aging and regulated protein degradation: who has the UPPer hand? Aging Cell 2007;6:599-606
   PubMed Web of Science ®Google Scholar
• Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006;443:787-95
   PubMed Web of Science ®Google Scholar
• Prusiner SB, Hsiao KK. Human prion diseases. Ann Neurol 1994;35:385-95
   PubMed Web of Science ®Google Scholar
• Heppner FL, Christ AD, Klein MA, et al. Transepithelial prion transport by M cells. Nat Med 2001;7:976-7
   PubMed Web of Science ®Google Scholar
• Perry VH, Cunningham C, Boche D. Atypical inflammation in the central nervous system in prion disease. Curr Opin Neurol 2002;15:349-54
   PubMed Web of Science ®Google Scholar
• Mabbott NA. The complement system in prion diseases. Curr Opin Immunol 2004;16:587-93
   PubMed Web of Science ®Google Scholar
• Hauwel M, Furon E, Canova C, et al. Innate (inherent) control of brain infection, brain inflammation and brain repair: the role of microglia, astrocytes, “protective” glial stem cells and stromal ependymal cells. Brain Res Brain Res Rev 2005;48:220-33
   PubMed Web of Science ®Google Scholar
• El Khoury J, Toft M, Hickman SE, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 2007;13:432-8
   PubMed Web of Science ®Google Scholar
• Brown DR. Microglia and prion disease. Microsc Res Tech 2001;54:71-80
   PubMed Web of Science ®Google Scholar
• Perry VH. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav Immun 2004;18:407-13
   PubMed Web of Science ®Google Scholar
• Carson MJ, Doose JM, Melchior B, et al. CNS immune privilege: hiding in plain sight. Immunol Rev 2006;213:48-65
   PubMed Web of Science ®Google Scholar
• Weissmann C, Raeber AJ, Montrasio F, et al. Prions and the lymphoreticular system. Philos Trans R Soc Lond B Biol Sci 2001;356:177-84
   PubMed Web of Science ®Google Scholar
• Caughey B, Raymond GJ. The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. J Biol Chem 1991;266:18217-23
   PubMed Web of Science ®Google Scholar
• Borchelt DR, Taraboulos A, Prusiner SB. Evidence for synthesis of scrapie prion proteins in the endocytic pathway. J Biol Chem 1992;267:16188-99
   PubMed Web of Science ®Google Scholar
• Serio TR, Cashikar AG, Kowal AS, et al. Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science 2000;289:1317-21
   PubMed Web of Science ®Google Scholar
• Caughey B. Prion protein conversions: insight into mechanisms, TSE transmission barriers and strains. Br Med Bull 2003;66:109-20
   PubMed Web of Science ®Google Scholar
• Soto C, Estrada L, Castilla J. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem Sci 2006;31:150-5
   PubMed Web of Science ®Google Scholar
• Bertsch U, Winklhofer KF, Hirschberger T, et al. Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets. J Virol 2005;79:7785-91
   PubMed Web of Science ®Google Scholar
• Breydo L, Bocharova OV, Baskakov IV. Semiautomated cell-free conversion of prion protein: applications for high-throughput screening of potential antiprion drugs. Anal Biochem 2005;339:165-73
   PubMed Web of Science ®Google Scholar
• Legname G, Baskakov IV, Nguyen HO, et al. Synthetic mammalian prions. Science 2004;305:673-6
   PubMed Web of Science ®Google Scholar
• Riesner D. Biochemistry and structure of PrP(C) and PrP(Sc). Br Med Bull 2003;66:21-33
   PubMed Web of Science ®Google Scholar
• Kocisko DA, Baron GS, Rubenstein R, et al. New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J Virol 2003;77:10288-94
   PubMed Web of Science ®Google Scholar
• Kocisko DA, Caughey B. Searching for anti-prion compounds: cell-based high-throughput in vitro assays and animal testing strategies. Methods Enzymol 2006;412:223-34
   PubMed Web of Science ®Google Scholar
• Bach S, Talarek N, Andrieu T, et al. Isolation of drugs active against mammalian prions using a yeast-based screening assay. Nat Biotechnol 2003;21:1075-81
   PubMed Web of Science ®Google Scholar
• Cronier S, Beringue V, Bellon A, et al. Prion strain- and species-dependent effects of antiprion molecules in primary neuronal cultures. J Virol 2007;81:13794-800
   PubMed Web of Science ®Google Scholar
• Larramendy-Gozalo C, Barret A, Daudigeos E, et al. Comparison of CR36, a new heparan mimetic, and pentosan polysulfate in the treatment of prion diseases. J Gen Virol 2007;88:1062-7
   PubMed Web of Science ®Google Scholar
• Shyng SL, Lehmann S, Moulder KL, et al. Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells. J Biol Chem 1995;270:30221-9
   PubMed Web of Science ®Google Scholar
• Horonchik L, Tzaban S, Ben Zaken O, et al. Heparan sulfate is a cellular receptor for purified infectious prions. J Biol Chem 2005;280:17062-7
   PubMed Web of Science ®Google Scholar
• Hijazi N, Kariv-Inbal Z, Gasset M, et al. PrPSc incorporation to cells requires endogenous glycosaminoglycan expression. J Biol Chem 2005;280:17057-61
   PubMed Web of Science ®Google Scholar
• Wong C, Xiong LW, Horiuchi M, et al. Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. EMBO J 2001;20:377-86
   PubMed Web of Science ®Google Scholar
• Diringer H, Ehlers B. Chemoprophylaxis of scrapie in mice. J Gen Virol 1991;72(Pt 2):457-60
   PubMed Web of Science ®Google Scholar
• Farquhar CF, Dickinson AG. Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. J Gen Virol 1986;67(Pt 3):463-73
   PubMed Web of Science ®Google Scholar
• Ladogana A, Casaccia P, Ingrosso L, et al. Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. J Gen Virol 1992;73(Pt 3):661-5
   PubMed Web of Science ®Google Scholar
• Doh-Ura K, Ishikawa K, Murakami-Kubo I, et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol 2004;78:4999-5006
   PubMed Web of Science ®Google Scholar
• Caughey B, Race RE. Potent inhibition of scrapie-associated PrP accumulation by Congo red. J Neurochem 1992;59:768-71
   PubMed Web of Science ®Google Scholar
• Adjou KT, Simoneau S, Sales N, et al. A novel generation of heparan sulfate mimetics for the treatment of prion diseases. J Gen Virol 2003;84:2595-603
   PubMed Web of Science ®Google Scholar
• Schonberger O, Horonchik L, Gabizon R, et al. Novel heparan mimetics potently inhibit the scrapie prion protein and its endocytosis. Biochem Biophys Res Commun 2003;312:473-9
   PubMed Web of Science ®Google Scholar
• Gilch S, Winklhofer KF, Groschup MH, et al. Intracellular re-routing of prion protein prevents propagation of PrP(Sc) and delays onset of prion disease. EMBO J 2001;20:3957-66
   PubMed Web of Science ®Google Scholar
• Caughey B, Ernst D, Race RE. Congo red inhibition of scrapie agent replication. J Virol 1993;67:6270-2
   PubMed Web of Science ®Google Scholar
• Ingrosso L, Ladogana A, Pocchiari M. Congo red prolongs the incubation period in scrapie-infected hamsters. J Virol 1995;69:506-8
   PubMed Web of Science ®Google Scholar
• Poli G, Martino PA, Villa S, et al. Evaluation of anti-prion activity of Congo red and its derivatives in experimentally infected hamsters. Arzneimittelforschung 2004;54:406-15
   PubMed Web of Science ®Google Scholar
• Caspi S, Halimi M, Yanai A, et al. The anti-prion activity of Congo red. Putative mechanism. J Biol Chem 1998;273:3484-9
   PubMed Web of Science ®Google Scholar
• Vey M, Pilkuhn S, Wille H, et al. Subcellular colocalization of the cellular and scrapie prion proteins in caveolae-like membranous domains. Proc Natl Acad Sci USA 1996;93:14945-9
   PubMed Web of Science ®Google Scholar
• Taraboulos A, Scott M, Semenov A, et al. Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J Cell Biol 1995;129:121-32
   PubMed Web of Science ®Google Scholar
• Bate C, Salmona M, Diomede L, et al. Squalestatin cures prion-infected neurons and protects against prion neurotoxicity. J Biol Chem 2004;279:14983-90
   PubMed Web of Science ®Google Scholar
• Gilch S, Kehler C, Schatzl HM. The prion protein requires cholesterol for cell surface localization. Mol Cell Neurosci 2006;31:346-53
   PubMed Web of Science ®Google Scholar
• Wilson R, Bate C, Boshuizen R, et al. Squalestatin alters the intracellular trafficking of a neurotoxic prion peptide. BMC Neurosci 2007;8:99. Published online 22 November 2007, doi:10.1186/1471-2202-8-99
   PubMedGoogle Scholar
• Mange A, Nishida N, Milhavet O, et al. Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures. J Virol 2000;74:3135-40
   PubMed Web of Science ®Google Scholar
• Pocchiari M, Schmittinger S, Masullo C. Amphotericin B delays the incubation period of scrapie in intracerebrally inoculated hamsters. J Gen Virol 1987;68(Pt 1):219-23
   PubMed Web of Science ®Google Scholar
• McKenzie D, Kaczkowski J, Marsh R, et al. Amphotericin B delays both scrapie agent replication and PrP-res accumulation early in infection. J Virol 1994;68:7534-6
   PubMed Web of Science ®Google Scholar
• Demaimay R, Adjou K, Lasmezas C, et al. Pharmacological studies of a new derivative of amphotericin B, MS-8209, in mouse and hamster scrapie. J Gen Virol 1994;75(Pt 9):2499-503
   PubMed Web of Science ®Google Scholar
• Adjou KT, Demaimay R, Lasmezas C, et al. MS-8209, a new amphotericin B derivative, provides enhanced efficacy in delaying hamster scrapie. Antimicrob Agents Chemother 1995;39:2810-2
   PubMed Web of Science ®Google Scholar
• Adjou KT, Demaimay R, Deslys JP, et al. MS-8209, a water-soluble amphotericin B derivative, affects both scrapie agent replication and PrPres accumulation in Syrian hamster scrapie. J Gen Virol 1999;80(Pt 4):1079-85
   PubMed Web of Science ®Google Scholar
• Adjou KT, Demaimay R, Lasmezas CI, et al. Differential effects of a new amphotericin B derivative, MS-8209, on mouse BSE and scrapie: implications for the mechanism of action of polyene antibiotics. Res Virol 1996;147:213-8
   PubMedGoogle Scholar
• Caughey WS, Raymond LD, Horiuchi M, et al. Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc Natl Acad Sci USA 1998;95:12117-22
   PubMed Web of Science ®Google Scholar
• Priola SA, Raines A, Caughey WS. Porphyrin and phthalocyanine antiscrapie compounds. Science 2000;287:1503-6
   PubMed Web of Science ®Google Scholar
• Priola SA, Raines A, Caughey W. Prophylactic and therapeutic effects of phthalocyanine tetrasulfonate in scrapie-infected mice. J Infect Dis 2003;188:699-705
   PubMed Web of Science ®Google Scholar
• Forloni G, Iussich S, Awan T, et al. Tetracyclines affect prion infectivity. Proc Natl Acad Sci USA 2002;99:10849-54
   PubMed Web of Science ®Google Scholar
• Kocisko DA, Caughey WS, Race RE, et al. A porphyrin increases survival time of mice after intracerebral prion infection. Antimicrob Agents Chemother 2006;50:759-61
   PubMed Web of Science ®Google Scholar
• Caughey WS, Priola SA, Kocisko DA, et al. Cyclic tetrapyrrole sulfonation, metals, and oligomerization in antiprion activity. Antimicrob Agents Chemother 2007;51:3887-94
   PubMed Web of Science ®Google Scholar
• Supattapone S, Nguyen HO, Cohen FE, et al. Elimination of prions by branched polyamines and implications for therapeutics. Proc Natl Acad Sci USA 1999;96:14529-34
   PubMed Web of Science ®Google Scholar
• Supattapone S, Wille H, Uyechi L, et al. Branched polyamines cure prion-infected neuroblastoma cells. J Virol 2001;75:3453-61
   PubMed Web of Science ®Google Scholar
• Winklhofer KF, Tatzelt J. Cationic lipopolyamines induce degradation of PrPSc in scrapie-infected mouse neuroblastoma cells. Biol Chem 2000;381:463-9
   PubMed Web of Science ®Google Scholar
• Solassol J, Crozet C, Perrier V, et al. Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie. J Gen Virol 2004;85:1791-9
   PubMed Web of Science ®Google Scholar
• Doh-Ura K, Iwaki T, Caughey B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 2000;74:4894-7
   PubMed Web of Science ®Google Scholar
• Doh-Ura K, Mekada E, Ogomori K, et al. Enhanced CD9 expression in the mouse and human brains infected with transmissible spongiform encephalopathies. J Neuropathol Exp Neurol 2000;59:774-85
   PubMed Web of Science ®Google Scholar
• Korth C, May BC, Cohen FE, et al. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 2001;98:9836-41
   PubMed Web of Science ®Google Scholar
• May BC, Fafarman AT, Hong SB, et al. Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc Natl Acad Sci USA 2003;100:3416-21
   PubMed Web of Science ®Google Scholar
• Ertmer A, Gilch S, Yun SW, et al. The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells. J Biol Chem 2004;279:41918-27
   PubMed Web of Science ®Google Scholar
• Ertmer A, Huber V, Gilch S, et al. The anticancer drug imatinib induces cellular autophagy. Leukemia 2007;21:936-42
   PubMed Web of Science ®Google Scholar
• Yun SW, Ertmer A, Flechsig E, et al. The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the periphery. J Neurovirol 2007;13:328-37
   PubMed Web of Science ®Google Scholar
• Tilly G, Chapuis J, Vilette D, et al. Efficient and specific down-regulation of prion protein expression by RNAi. Biochem Biophys Res Commun 2003;305:548-51
   PubMed Web of Science ®Google Scholar
• Daude N, Marella M, Chabry J. Specific inhibition of pathological prion protein accumulation by small interfering RNAs. J Cell Sci 2003;116:2775-9
   PubMed Web of Science ®Google Scholar
• Pfeifer A. Lentiviral transgenesis – a versatile tool for basic research and gene therapy. Curr Gene Ther 2006;6:535-42
   PubMed Web of Science ®Google Scholar
• Golding MC, Long CR, Carmell MA, et al. Suppression of prion protein in livestock by RNA interference. Proc Natl Acad Sci USA 2006;103:5285-90
   PubMed Web of Science ®Google Scholar
• Pfeifer A, Eigenbrod S, Al Khadra S, et al. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J Clin Invest 2006;116:3204-10
   PubMed Web of Science ®Google Scholar
• Kocisko DA, Vaillant A, Lee KS, et al. Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides. Antimicrob Agents Chemother 2006;50:1034-44
   PubMed Web of Science ®Google Scholar
• Karpuj MV, Giles K, Gelibter-Niv S, et al. Phosphorothioate oligonucleotides reduce PrP levels and prion infectivity in cultured cells. Mol Med 2007;13:190-8
   PubMed Web of Science ®Google Scholar
• Proske D, Gilch S, Wopfner F, et al. Prion-protein-specific aptamer reduces PrPSc formation. Chembiochem 2002;3:717-25
   PubMed Web of Science ®Google Scholar
• Sethi S, Lipford G, Wagner H, et al. Postexposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet 2002;360:229-30
   PubMed Web of Science ®Google Scholar
• Heikenwalder M, Polymenidou M, Junt T, et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004;10:187-92
   PubMed Web of Science ®Google Scholar
• Chabry J, Priola SA, Wehrly K, et al. Species-independent inhibition of abnormal prion protein (PrP) formation by a peptide containing a conserved PrP sequence. J Virol 1999;73:6245-50
   PubMed Web of Science ®Google Scholar
• Horiuchi M, Baron GS, Xiong LW, et al. Inhibition of interactions and interconversions of prion protein isoforms by peptide fragments from the C-terminal folded domain. J Biol Chem 2001;276:15489-97
   PubMed Web of Science ®Google Scholar
• Gilch S, Kehler C, Schatzl HM. Peptide aptamers expressed in the secretory pathway interfere with cellular PrPSc formation. J Mol Biol 2007;371:362-73
   PubMed Web of Science ®Google Scholar
• Horiuchi M. Prion diseases in animals. Uirusu 2001;51:145-50
   PubMedGoogle Scholar
• Colas P, Cohen B, Jessen T, et al. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature 1996;380:548-50
   PubMed Web of Science ®Google Scholar
• Soto C, Kascsak RJ, Saborio GP, et al. Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet 2000;355:192-7
   PubMed Web of Science ®Google Scholar
• Peretz D, Williamson RA, Kaneko K, et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 2001;412:739-43
   PubMed Web of Science ®Google Scholar
• Enari M, Flechsig E, Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci USA 2001;98:9295-9
   PubMed Web of Science ®Google Scholar
• Pankiewicz J, Prelli F, Sy MS, et al. Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur J Neurosci 2006;23:2635-47
   PubMed Web of Science ®Google Scholar
• Feraudet C, Morel N, Simon S, et al. Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells. J Biol Chem 2005;280:11247-58
   PubMed Web of Science ®Google Scholar
• Perrier V, Solassol J, Crozet C, et al. Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation. J Neurochem 2004;89:454-63
   PubMed Web of Science ®Google Scholar
• Gilch S, Wopfner F, Renner-Muller I, et al. Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. J Biol Chem 2003;278:18524-31
   PubMed Web of Science ®Google Scholar
• Oboznaya MB, Gilch S, Titova MA, et al. Antibodies to a nonconjugated prion protein peptide 95-123 interfere with PrP Sc propagation in prion-infected cells. Cell Mol Neurobiol 2007; 273:271-84
   Google Scholar
• Beringue V, Vilette D, Mallinson G, et al. PrPSc binding antibodies are potent inhibitors of prion replication in cell lines. J Biol Chem 2004;279:39671-6
   PubMed Web of Science ®Google Scholar
• Donofrio G, Heppner FL, Polymenidou M, et al. Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies. J Virol 2005;79:8330-8
   PubMed Web of Science ®Google Scholar
• Cardinale A, Filesi I, Vetrugno V, et al. Trapping prion protein in the endoplasmic reticulum impairs PrPC maturation and prevents PrPSc accumulation. J Biol Chem 2005;280:685-94
   PubMed Web of Science ®Google Scholar
• Vetrugno V, Cardinale A, Filesi I, et al. KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity. Biochem Biophys Res Commun 2005;338:1791-7
   PubMed Web of Science ®Google Scholar
• Zuber C, Knackmuss S, Rey C, et al. Single chain Fv antibodies directed against the 37 kDa/67 kDa laminin receptor as therapeutic tools in prion diseases. Mol Immunol 2008;45:144-51
   PubMed Web of Science ®Google Scholar
• Heppner FL, Musahl C, Arrighi I, et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 2001;294:178-82
   PubMed Web of Science ®Google Scholar
• White AR, Enever P, Tayebi M, et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003;422:80-3
   PubMed Web of Science ®Google Scholar
• Schwarz A, Kratke O, Burwinkel M, et al. Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci Lett 2003;350:187-9
   PubMed Web of Science ®Google Scholar
• Handisurya A, Gilch S, Winter D, et al. Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells. FEBS J 2007;274:1747-58
   PubMed Web of Science ®Google Scholar
• Arbel M, Lavie V, Solomon B. Generation of antibodies against prion protein in wild-type mice via helix 1 peptide immunization. J Neuroimmunol 2003;144:38-45
   PubMed Web of Science ®Google Scholar
• Souan L, Tal Y, Felling Y, et al. Modulation of proteinase-K resistant prion protein by prion peptide immunization. Eur J Immunol 2001;31:2338-46
   PubMed Web of Science ®Google Scholar
• Bainbridge J, Jones N, Walker B. Multiple antigenic peptides facilitate generation of anti-prion antibodies. Clin Exp Immunol 2004;137:298-304
   PubMed Web of Science ®Google Scholar
• Sigurdsson EM, Brown DR, Daniels M, et al. Immunization delays the onset of prion disease in mice. Am J Pathol 2002;161:13-7
   PubMed Web of Science ®Google Scholar
• Wisniewski T, Sigurdsson EM. Immunization treatment approaches in Alzheimer's and prion diseases. Curr Neurol Neurosci Rep 2002;2:400-4
   PubMedGoogle Scholar
• Koller MF, Grau T, Christen P. Induction of antibodies against murine full-length prion protein in wild-type mice. J Neuroimmunol 2002;132:113-6
   PubMed Web of Science ®Google Scholar
• Polymenidou M, Heppner FL, Pellicioli EC, et al. Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc Natl Acad Sci USA 2004;101(Suppl 2):14670-6
   PubMed Web of Science ®Google Scholar
• Kaiser-Schulz G, Heit A, Quintanilla-Martinez L, et al. Polylactide-coglycolide microspheres co-encapsulating recombinant tandem prion protein with CpG-oligonucleotide break self-tolerance to prion protein in wild-type mice and induce CD4 and CD8 T cell responses. J Immunol 2007;179:2797-807
   PubMed Web of Science ®Google Scholar
• Fernandez-Borges N, Brun A, Whitton JL, et al. DNA vaccination can break immunological tolerance to PrP in wild-type mice and attenuates prion disease after intracerebral challenge. J Virol 2006;80:9970-6
   PubMed Web of Science ®Google Scholar
• Nikles D, Bach P, Boller K, et al. Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP. J Virol 2005;79:4033-42
   PubMed Web of Science ®Google Scholar
• Goni F, Knudsen E, Schreiber F, et al. Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 2005;133:413-21
   PubMed Web of Science ®Google Scholar
• Todd NV, Morrow J, Doh-Ura K, et al. Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease. J Infect 2005;50:394-6
   PubMed Web of Science ®Google Scholar
• Whittle IR, Knight RS, Will RG. Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt-Jakob disease. Acta Neurochir (Wien) 2006;148:677-9
   PubMed Web of Science ®Google Scholar
• Parry A, Baker I, Stacey R, et al. Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate. J Neurol Neurosurg Psychiatry 2007;78:733-4
   PubMed Web of Science ®Google Scholar
• Barret A, Tagliavini F, Forloni G, et al. Evaluation of quinacrine treatment for prion diseases. J Virol 2003;77:8462-9
   PubMed Web of Science ®Google Scholar
• Benito-Leon J. Combined quinacrine and chlorpromazine therapy in fatal familial insomnia. Clin Neuropharmacol 2004;27:201-3
   PubMed Web of Science ®Google Scholar
• Haik S, Brandel JP, Salomon D, et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology 2004;63:2413-5
   PubMed Web of Science ®Google Scholar
• Perovic S, Pergande G, Ushijima H, et al. Flupirtine partially prevents neuronal injury induced by prion protein fragment and lead acetate. Neurodegeneration 1995;4:369-74
   PubMedGoogle Scholar
• Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology 2004;62:714-8
   PubMed Web of Science ®Google Scholar